Updates are available Correction dated 2023-06-20
Click to view Correction: https://doi.org/10.1038/s41586-023-06088-3
-
Authors
Labanieh, Louai
Mackall, Crystal L. http://orcid.org/0000-0001-6323-4304
- License Information
-
More Information
Article History
Received: 5 March 2022
Accepted: 4 January 2023
First Online: 22 February 2023
Change Date: 20 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-023-06088-3
Competing interests
: L.L. and C.L.M. are inventors on several patents related to CAR T cell therapies. C.L.M. is a cofounder of Lyell Immunopharma, CARGO Therapeutics and Link Cell Therapies, which are developing CAR-based therapies, and consults for Lyell, Syncopation, Link, Apricity, Nektar, Immatics, Ensoma, Mammoth, Glaxo Smith Kline and Bristol Myers Squibb. L.L. is a cofounder of, consults for, and holds equity in CARGO Therapeutics. L.L. is a consultant for and holds equity in Lyell Immunopharma.
